Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
The panel distinguishes between patients with non-aggressive disease and more aggressive forms that could require interventions like radical prostatectomy.
The assay measures the levels of three metabolites in patient urine to detect adenomatous polyps, and is being offered as a laboratory-developed test by ADL.
The test was previously approved to detect and differentiate carbapenemase genes from bacterial isolates, and now has an expanded claim for testing directly from rectal swabs.
